Metraipolis › archive › dc_f68bb7d26312

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study — Europe PMC PMID:42109668

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42109668
DOI
10.3389/fonc.2026.1823568
License (as archived)
solo-consultazione
Archived
2026-11-03T07:36:43.483Z
SHA-256 of the archived text
a03e5b48a91dd077c5bbd2fac57b9609499fbf84754bd2dc16eb110ecd280c2f
Stable URL of this page
https://metraipolis.com/documento/dc_f68bb7d26312

How to cite

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study — Europe PMC PMID:42109668 — Europe PMC (en), https://europepmc.org/article/MED/42109668 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f68bb7d26312 (Metraipolis archive dc_f68bb7d26312, sha256 a03e5b48a91dd077c5bbd2fac57b9609499fbf84754bd2dc16eb110ecd280c2f)
BibTeX
@misc{dcf68bb7d26312,
  title = {Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study — Europe PMC PMID:42109668},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42109668},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f68bb7d26312; sha256 a03e5b48a91dd077c5bbd2fac57b9609499fbf84754bd2dc16eb110ecd280c2f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42109668. Agents can read the archived copy with the MCP tool read_document.